Overview

Gefitinib Combined With Thalidomide to Treat NSCLC

Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether thalidomide can improve the effectiveness of the gefitinib in NSCLC patients with EGFR mutations.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Bai Jun
Treatments:
Aspirin
Gefitinib
Thalidomide